Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma

OBJECTIVE: Sorafenib and lenvatinib have been recommended as standard tyrosine kinase inhibitors (TKIs) for progressive radioiodine-refractory differentiated thyroid carcinoma (RR-DTC). However, their efficacy remains limited with unresolved drug resistance. Therefore, we conceived this open-label s...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Xian, Cheng, Lin, Sa, Ri, Fu, Hao, Jin, Yuchen, Chen, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142807/
https://www.ncbi.nlm.nih.gov/pubmed/35060924
http://dx.doi.org/10.1530/ETJ-21-0065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142807/
https://www.ncbi.nlm.nih.gov/pubmed/35060924
http://dx.doi.org/10.1530/ETJ-21-0065

Ejemplares similares